Presentation is loading. Please wait.

Presentation is loading. Please wait.

POSEIDON-DCM Trial design: Patients with nonischemic dilated cardiomyopathy were randomized to transendocardial injection of allogenic (n = 18) vs. autologous.

Published byἌδραστος Μητσοτάκης Modified over 5 years ago

Similar presentations

Presentation on theme: "POSEIDON-DCM Trial design: Patients with nonischemic dilated cardiomyopathy were randomized to transendocardial injection of allogenic (n = 18) vs. autologous."— Presentation transcript:

1 POSEIDON-DCM Trial design: Patients with nonischemic dilated cardiomyopathy were randomized to transendocardial injection of allogenic (n = 18) vs. autologous stem cells (n = 16). (p = ns) Results Treatment-emergent serious adverse events within 30 days: none of the allogenic stem cell group vs. none of the autologous stem cell group Serious adverse events at 12 months: 28% in the allogenic group vs. 64% in the autologous group (p = 0.10) % Conclusions Among patients with a nonischemic dilated cardiomyopathy, transendocardial injection of bone marrow-derived stem cells (allogenic vs. autologous) was feasible This small pilot study demonstrated the safety of endocardial stem cell injection Allogenic group Autologous group Hare JM, et al. J Am Coll Cardiol 2016;Nov 14:[Epub]

Download ppt "POSEIDON-DCM Trial design: Patients with nonischemic dilated cardiomyopathy were randomized to transendocardial injection of allogenic (n = 18) vs. autologous."

Similar presentations

© 2012 EuroIntervention. All rights reserved. EuroIntervention 2012;8:732-742 Percutaneous, transendocardial injection of bone marrow-derived mononuclear.

© 2012 EuroIntervention. All rights reserved. EuroIntervention 2012;8: Percutaneous, transendocardial injection of bone marrow-derived mononuclear.
Stem Cell Implants to Repair Damaged Hearts Rationale Two clinical trials – Cardiac-derived stem cells Cedars Sinai Medical Center, Dr. Eduardo Marban.

Stem Cell Implants to Repair Damaged Hearts Rationale Two clinical trials – Cardiac-derived stem cells Cedars Sinai Medical Center, Dr. Eduardo Marban.
By MD., FAC.C Zagazig University. 1.Improve endothelial function 2.Stimulate angiogenesis 3.Mobilize bone-marrow derived stem cells 4.Reduce systemic.

By MD., FAC.C Zagazig University. 1.Improve endothelial function 2.Stimulate angiogenesis 3.Mobilize bone-marrow derived stem cells 4.Reduce systemic.
S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Selective heart rate reduction with ivabradine unloads the left ventricle in.

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Selective heart rate reduction with ivabradine unloads the left ventricle in.
Patient disposition Dichtl W, et al. Am J Cardiol. 2008;102:743-8 AVR = aortic valve replacement; MDCT = multidetector computed tomographic.

Patient disposition Dichtl W, et al. Am J Cardiol. 2008;102:743-8 AVR = aortic valve replacement; MDCT = multidetector computed tomographic.
Hsia J et al. J Am Coll Cardiol 2011;57:1666-75. Baseline Characteristics by Treatment Group and Attained LDL-C Hsia J et al. J Am Coll Cardiol 2011;57:1666-75.

Hsia J et al. J Am Coll Cardiol 2011;57: Baseline Characteristics by Treatment Group and Attained LDL-C Hsia J et al. J Am Coll Cardiol 2011;57:
Skeletal Myoblast Cells. 2 Skeletal myoblasts Derived from satellite cells in skeletal muscle With appropriate stimulus, satellite cells differentiate.

Skeletal Myoblast Cells. 2 Skeletal myoblasts Derived from satellite cells in skeletal muscle With appropriate stimulus, satellite cells differentiate.
(p for noninferiority = 0.01)

(p for noninferiority = 0.01)
1 Stone RM et al. Proc ASH 2015;Abstract 6.

1 Stone RM et al. Proc ASH 2015;Abstract 6.
Stem Cell doubling is logarithmic

Stem Cell doubling is logarithmic
IFM/DFCI 2009 Trial: Autologous Stem Cell Transplantation (ASCT) for Multiple Myeloma (MM) in the Era of New Drugs Phase III study of lenalidomide/bortezomib/dexamethasone.

IFM/DFCI 2009 Trial: Autologous Stem Cell Transplantation (ASCT) for Multiple Myeloma (MM) in the Era of New Drugs Phase III study of lenalidomide/bortezomib/dexamethasone.
Fig 1: Microscopic Spindle shaped MSCs Fig 2: Method of MSCs Injection

Fig 1: Microscopic Spindle shaped MSCs Fig 2: Method of MSCs Injection
EBMT Activity Survey Teams Patients Transplants

EBMT Activity Survey Teams Patients Transplants
Harrison CN et al. Proc ASH 2015;Abstract 59.

Harrison CN et al. Proc ASH 2015;Abstract 59.
(CMR vs. guidelines, p < 0.001)

(CMR vs. guidelines, p < 0.001)
EARLY-BAMI Trial design: Patients presenting with STEMI with a plan for primary PCI, and without evidence of cardiogenic shock, were randomized to either.

EARLY-BAMI Trial design: Patients presenting with STEMI with a plan for primary PCI, and without evidence of cardiogenic shock, were randomized to either.
RE-CIRCUIT Trial design: Patients with atrial fibrillation undergoing catheter ablation were randomized to uninterrupted dabigatran 150 mg twice daily.

RE-CIRCUIT Trial design: Patients with atrial fibrillation undergoing catheter ablation were randomized to uninterrupted dabigatran 150 mg twice daily.
BENEFIT Trial design: Patients with positive serologic tests for T. Cruzi and cardiomyopathy were randomized to benznidazole 300 mg daily for 40-80 days.

BENEFIT Trial design: Patients with positive serologic tests for T. Cruzi and cardiomyopathy were randomized to benznidazole 300 mg daily for days.
Phase 2 Treatment Naïve Injection Drug Use

Phase 2 Treatment Naïve Injection Drug Use
AcoArt I Trial design: Patients with femoropopliteal artery disease were randomized to paclitaxel-coated balloon angioplasty (n = 100) vs. standard peripheral.

AcoArt I Trial design: Patients with femoropopliteal artery disease were randomized to paclitaxel-coated balloon angioplasty (n = 100) vs. standard peripheral.

Similar presentations

Ads by Google